STOXX 600Health Care· Belgium

UCB

Challenger

UCB

$263.90

+2.01%

Open $255.00·Prev $258.70

as of 17 Apr

CHALLENGER

Power Core

UCB's moat is dual IL-17 inhibition via BIMZELX, a bispecific antibody that simultaneously neutralizes both IL-17A and IL-17F, creating a differentiated efficacy profile that competitors cannot replicate without developing their own bispecific molecules from scratch.

Published18 Apr 2026

UniverseSTOXX 600

SectorHealth Care

↑

Direction of Movement

upward

ROC 200

+62.2%

Financials